A Phase III study of PTI-428, PTI-808 and PTI-801 combination
Phase of Trial: Phase III
Latest Information Update: 13 Jan 2020
Price : $35 *
At a glance
- Drugs PTI 428 (Primary) ; PTI 808 (Primary) ; PTI NC 733 (Primary) ; PTI-801 Proteostasis Therapeutics (Primary)
- Indications Cystic fibrosis
- Focus Registrational; Therapeutic Use
- Acronyms MORE
- Sponsors Proteostasis Therapeutics
- 13 Jan 2020 According to a Proteostasis Therapeutics media release, the company completed a scientific advice meeting with the Medicines and Healthcare Products Regulatory Agency (MHRA), UK
- 17 Dec 2019 According to a Proteostasis Therapeutics media release, this trial is expected to begin in 2020.
- 20 Dec 2018 According to a Proteostasis Therapeutics media release, assuming positive results from doublet and triplet studies, the company expect to be in a position to initiate Phase 3 studies within the next 12-18 months.